{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:59:22Z","timestamp":1791644362088,"version":"4.3.4"},"reference-count":34,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2021,6,2]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Sodium\n                      <jats:sup>+<\/jats:sup>\n                      \/ taurocholate cotransporting polypeptide (NTCP) is a membrane transporter affecting the enterohepatic circulation of bile acids (BAs). We aimed to evaluate NTCP\u2019s roles in humans and animal models of liver fibrosis (LF).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      Primary hepatic stellate cells (pHSCs) isolated from livers biopsies of patients with LF with different fibrosis grading were stained for NTCP. NTCP gene silencing, taurocholic acid (TCA), obeticholic acid (OCA), epigallocatechin gallate (EGCG) and HA-100 dihydrochloride (HA-100) were used as tools to modulate NTCP expression on human HSC line (LX2). BA trafficking\/uptake were assessed extracellularly (LX2 culture medium) and intracellularly following treatment with\/without NTCP neutralizing antibody. LF models of C57\/BL6 mice of carbon tetrachloride (CCl\n                      <jats:sub>4<\/jats:sub>\n                      ) and leptin-deficient (\n                      <jats:italic>Ob\/Ob<\/jats:italic>\n                      ) fed with high-fat diet (\n                      <jats:italic>\n                        Ob\/Ob\n                        <jats:sup>HFD<\/jats:sup>\n                      <\/jats:italic>\n                      ) were evaluated for pHSCs-NTCP expressions, metabolic and LF profiles following intraperitoneal injections of NTCP neutralizing antibody.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      pHSCs from F3\/F4-scored patients of LF exhibit threefold increased NTCP expressions compared with F0-scored patients (p&lt;0.0001). Sorted-activated HSCs (LX2\n                      <jats:sup>\u03b1SMA+<\/jats:sup>\n                      ) showed high expressions of NTCP and high TCA uptake in vitro and triggered a further increase in their activations. This phenomenon was inhibited with NTCP small interfering RNA and the NTCP neutralizing antibody. Sorted LX2\n                      <jats:sup>NTCP+<\/jats:sup>\n                      (high alpha smooth muscle actin (\u03b1SMA)\/high NTCP) cells showed high phosphorylated pathways of AKT\/mTOR and protein kinase C (PKC) accompanied with a decrease in farnesoid X receptor expression. Moreover, LX2\n                      <jats:sup>NTCP+<\/jats:sup>\n                      cells treated with EGCG, OCA and PKC inhibitor HA-100 significantly decreased NTCP and \u03b1SMA. NTCP neutralizing antibody inhibited NTCP (less TCA uptake); it attenuated LF in both CCl\n                      <jats:sub>4<\/jats:sub>\n                      and\n                      <jats:italic>\n                        Ob\/Ob\n                        <jats:sup>HFD<\/jats:sup>\n                      <\/jats:italic>\n                      animal models with ameliorated metabolic profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NTCP expression is linearly correlated with fibrosis severity. Modulated BA trafficking could be an important step in LF pathogenesis. Antagonising BA uptake may suggest a therapeutic strategy for preventing disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2020-323345","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T13:21:23Z","timestamp":1626355283000},"page":"1373-1385","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Sodium\n                    <sup>+<\/sup>\n                    \/taurocholate cotransporting polypeptide as target therapy for liver fibrosis"],"prefix":"10.1136","volume":"71","author":[{"given":"Ahmad","family":"Salhab","sequence":"first","affiliation":[{"name":"Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5828-6783","authenticated-orcid":false,"given":"Johnny","family":"Amer","sequence":"additional","affiliation":[{"name":"Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Lu","sequence":"additional","affiliation":[{"name":"Comprehensive Liver Cancer Center, The Fifth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[{"name":"Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"2026062605051274000_71.7.1373.1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000450983","article-title":"Bile acid uptake transporters as targets for therapy","volume":"35","author":"Slijepcevic","year":"2017","journal-title":"Dig Dis"},{"key":"2026062605051274000_71.7.1373.2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tiv.2017.10.012","article-title":"Kinetic characterization of bile salt transport by human Ntcp (SLC10A1)","volume":"46","author":"Jani","year":"2018","journal-title":"Toxicol In Vitro"},{"key":"2026062605051274000_71.7.1373.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15338-0","article-title":"Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter Ntcp","volume":"7","author":"Donkers","year":"2017","journal-title":"Sci Rep"},{"key":"2026062605051274000_71.7.1373.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.08.002"},{"key":"2026062605051274000_71.7.1373.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.10.007"},{"key":"2026062605051274000_71.7.1373.6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.33594\/000000100","article-title":"Regulation of plasma membrane localization of the Na\u207a-Taurocholate co-transporting polypeptide by glycochenodeoxycholate and tauroursodeoxycholate","volume":"52","author":"Mayer","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"2026062605051274000_71.7.1373.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2018.05.011"},{"key":"2026062605051274000_71.7.1373.8","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2019.0043"},{"key":"2026062605051274000_71.7.1373.9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93558"},{"key":"2026062605051274000_71.7.1373.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.05.007"},{"key":"2026062605051274000_71.7.1373.11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017305","article-title":"Clinical and histopathologic features of sodium taurocholate cotransporting polypeptide deficiency in pediatric patients","volume":"98","author":"Dong","year":"2019","journal-title":"Medicine"},{"key":"2026062605051274000_71.7.1373.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.011"},{"key":"2026062605051274000_71.7.1373.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.09.008"},{"key":"2026062605051274000_71.7.1373.14","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R900012-JLR200"},{"key":"2026062605051274000_71.7.1373.15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29251"},{"key":"2026062605051274000_71.7.1373.16","doi-asserted-by":"crossref","DOI":"10.1038\/srep29358","article-title":"Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus","volume":"6","author":"Kaneko","year":"2016","journal-title":"Sci Rep"},{"key":"2026062605051274000_71.7.1373.17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/22221751.2019.1625728","article-title":"Down-Regulation of cell membrane localized Ntcp expression in proliferating hepatocytes prevents hepatitis B virus infection","volume":"8","author":"Yan","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"2026062605051274000_71.7.1373.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.09.009"},{"key":"2026062605051274000_71.7.1373.19","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2014.0581"},{"key":"2026062605051274000_71.7.1373.20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.33594\/000000140","article-title":"The therapeutic mechanisms of propolis against CCl\n                  4\n                -mediated liver injury by mediating apoptosis of activated hepatic stellate cells and improving the hepatic architecture through PI3K\/AKT\/mTOR, TGF-\u03b2\/Smad2, Bcl2\/BAX\/P53 and iNOS signaling pathways","volume":"53","author":"Badr","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"2026062605051274000_71.7.1373.21","doi-asserted-by":"crossref","DOI":"10.3390\/nu9101072","article-title":"Animal models of nonalcoholic fatty Liver disease\u2014a starter\u2019s guide","volume":"9","author":"Van Herck","year":"2017","journal-title":"Nutrients"},{"key":"2026062605051274000_71.7.1373.22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1751-2980.12378","article-title":"Role of farnesoid X receptor in cholestasis","volume":"17","author":"Yuan","year":"2016","journal-title":"J Dig Dis"},{"key":"2026062605051274000_71.7.1373.23","doi-asserted-by":"publisher","DOI":"10.1210\/me.2009-0286"},{"key":"2026062605051274000_71.7.1373.24","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.22.2647"},{"key":"2026062605051274000_71.7.1373.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.003"},{"key":"2026062605051274000_71.7.1373.26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cpt.744","article-title":"The NTCP-inhibitor Myrcludex B: effects on bile acid disposition and tenofovir pharmacokinetics","volume":"103","author":"Blank","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2026062605051274000_71.7.1373.27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27240"},{"key":"2026062605051274000_71.7.1373.28","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i16.673"},{"key":"2026062605051274000_71.7.1373.29","doi-asserted-by":"crossref","first-page":"127197","DOI":"10.1172\/jci.insight.127197","article-title":"NTCP deficiency in mice protects against obesity and hepatosteatosis","volume":"5","author":"Donkers","year":"2019","journal-title":"JCI Insight"},{"key":"2026062605051274000_71.7.1373.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.10.003"},{"key":"2026062605051274000_71.7.1373.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04697-5"},{"key":"2026062605051274000_71.7.1373.32","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.clinthera.2012.10.009","article-title":"Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract","volume":"34","author":"Halegoua-De Marzio","year":"2012","journal-title":"Clin Ther"},{"key":"2026062605051274000_71.7.1373.33","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2014.155"},{"key":"2026062605051274000_71.7.1373.34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.784322"}],"updated-by":[{"DOI":"10.1136\/gutjnl-2020-323345corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000}}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2020-323345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:05:28Z","timestamp":1782475528000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2020-323345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,6,7]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/gutjnl-2020-323345"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2020-323345","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]}}}